Genus plc to Announce Preliminary 2020 Year End Financial and Business Results on September 8, 2020

Sept. 4, 2020 12:30 UTC

 

World leader in animal genetics to webcast financial and operational highlights at 7:01 AM BST, 1:01 AM EDT

 

BASINGSTOKE, United Kingdom & MADISON, Wis.--(BUSINESS WIRE)-- Genus plc (LSE: GNS), a world leading animal genetics company producing superior breeding livestock through genetic improvement, today announced that it will release its preliminary financial results for the full year ended June 30, 2020, and provide a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses, on Tuesday, September 8, 2020.

Webcast Results Presentation
A pre-recorded briefing by management to discuss the preliminary results for the year ended June 30, 2020 will be held via a video webcast facility and will be accessible at the following link beginning at 7:01 AM BST, 1:01 AM EDT on September 8th: https://webcasting.buchanan.uk.com/broadcast/5f28011c65023062edd7e24a.

An archived recording of the webcast will also be available on the Investors section of the Company’s website.

About Genus
Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over 75 countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.

Genus’s competitive edge comes from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

Headquartered in Basingstoke, United Kingdom, Genus companies operate in over 25 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Contacts

Company Contacts:

Genus plc
Stephen Wilson, Chief Executive Officer
Alison Henriksen, Chief Financial Officer
Tel: 01256 345970

Investor Relations and Media Contacts:

United Kingdom
Buchanan
Charles Ryland / Chris Lane / Charlotte Slater
Tel: 0207 466 5000

United States
LaVoieHealthScience
Donna LaVoie / Sharon Choe / Paul Sagan
Tel: 617-374-8800
psagan@lavoiehealthscience.com

 
 

Source: Genus plc

Back to news